07/23 Taiwan BIO Weekly
2025-07-23 |
| Taiwan BIO Weekly |
| Gongwin Taiwan signs licensing deals to expand lung cancer drug markets 16 July, 2025 Biopharmaceutical company Gongwin Taiwan signed two key licensing agreements Wednesday to expand access to its innovative lung cancer drug PTS-302 in Taiwan and Malaysia, according to its parent company Gongwin Biopharm Co. (GBC). The first agreement, formalized with Malaysia-based Company F -- a pharmaceutical firm with over 30 years of experience in oncology and respiratory medicine -- follows a memorandum of understanding (MOU) signed in May, GBC said. More... |
| Taiwan's Glac Biotech probiotic approved by US FDA 16 July, 2025 Taiwan's leading ODM probiotic raw material manufacturer, Glac Biotech, has been awarded the "Generally Recognized As Safe" (GRAS, GRN001130) certification by the US Food and Drug Administration for its independently developed probiotic, Lactobacillus rhamnosus MP108. More... |
| HanchorBio's reports immunotherapy drug clinical success 15 July, 2025 HanchorBio (TW: 7827) announced that its innovative immunotherapy drug candidate HCB101 has demonstrated therapeutic potential in its latest clinical trial. At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, results from a Phase I trial involving 32 patients dosed at 0.08 to 5.12 mg/kg were presented. Among them, 6 patients showed stable disease (SD), including 5 patients with solid tumors who had failed multiple prior treatments. These patients achieved an average disease stabilization lasting over 16 weeks under HCB101 treatment. Furthermore, as the administered dose increased, more significant clinical efficacy continued to be confirmed. More... (in Chinese) |
| Transformative health solutions on display in Taipei 15 July May, 2025 Assistants for IV needle placement, advanced solutions for endoscopy, wound care and blood sampling, powerful AI tools to analyze medical images and reduce animal testing, and more: At Medical Taiwan 2025, manufacturers attracted attendees with a wide range of innovations. We took a closer look at some of the most exciting companies and their products on display at the medical, health and care expo, in alphabetical order. More... |
| Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors Press release 15 July, 2025 Senhwa Biosciences, Inc. (TW: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its new drug Pidnarulex (CX-5461) has been selected by the U.S. National Cancer Institute (NCI) as part of a five-year cancer research program. The first patient in the monotherapy clinical trial for advanced solid tumors has been successfully enrolled at the NIH Clinical Center in Bethesda, Maryland, USA. More... |
| Aging Populations and AI: Why Fujitsu's Partnership with Acer Medical Signals a New Era in Healthcare 15 July, 2025 The global population is aging rapidly, with the number of people over 65 projected to reach 1.5 billion by 2030. This demographic shift is straining healthcare systems worldwide, particularly in regions like Asia-Pacific, where aging populations are concentrated. Against this backdrop, AI-driven solutions are emerging as critical tools to address early disease detection, risk mitigation, and preventive care. A prime example is the strategic partnership between Fujitsu (6702.TYO) and [Taiwan's] Acer Medical (AMED), which has developed an AI-powered gait analysis system, aiGait, to tackle neurodegenerative diseases like dementia and Parkinson's. This collaboration not only highlights the potential for market leadership in elderly care but also underscores the scalability of AI across sectors--from sports medicine to pediatric neurology. More... |
| Atopic dermatitis may be linked to increased risk for chronic kidney disease 15 July, 2025 Atopic dermatitis (AD) was associated with an increased risk for chronic kidney disease (CKD) in an Asian population, according to a [Taiwan] study published online July 10 in the Journal of Dermatology. More... |
| BIO Asia–Taiwan brings together global and local biotech firms to pitch for investor attention 14 July, 2025 BIO Asia–Taiwan 2025, opening July 23rd in Taipei, Taiwan, will host a repeat of last year's popular and successful Investment Forum. The event promises to attract not only leading Taiwanese biotech firms, but also international biotech venture capitalists and startups assembling in Taiwan specifically to seek investment and partnerships. The forum will also host representatives from Taiwan’s well-funded information and communication technology (ICT) sector, family office managers, and nearly 50 domestic and international VC firms, setting up an unmatched opportunity for investors in this sector. More... |
| Acepodia targets Innovation Board listing, plans spin-off company with US investment 14 July, 2025 Acepodia-KY (TW: 6976), a cell therapy company, is actively advancing two novel cell therapy candidates; ACE1831 for blood cancers and ACE2016 for solid tumors.The company announced that it also plans to spin off its bispecific antibody-conjugated dual-drug platform into a new company, valuing the technology as part of the capital. The goal is to attract US investors and complete the company setup by the end of the year, with fundraising targeted at USD50 to 60 million. In addition, the company which is currently listed on the Emerging Stock Board, is aiming to uplist to the Taiwan Innovation Board in the second half of next year. More... (in Chinese) |
| Animal drug development company Protect Animal Health to debut on Emerging Stock Board in early August 14 July, 2025 Animal drug company Protect Animal Health (TW: 7850) is set to be listed on the Emerging Stock Board in early August. The company focuses on developing a comprehensive IP platform centered on animal pharmaceuticals. Its fastest-progressing product, PT101 for canine melanoma, is ready to enter field trials in Taiwan and the US, aiming for market launch in 2028. More... (in Chinese) |
| Precision Biotechnology reaches NT$100mill revenue within 3 years with AI-generated ECG tool 13 July, 2025 While a typical ECG diagnostic report takes from 40 to 50 minutes to complete, with AI technology it can be completed in just 4 minutes, claims Taiwanese startup Precision Biotechnology, whose flagship software product is making waves in the medical field. This software has not only helped the company establish a solid presence in the US market but is now being rolled out more extensively in Taiwan. Founded in 2022, Precision Biotechnology is still in its early startup phase. Yet in just three years, the company has achieved annual revenue of NT$100 million, with a striking 90 percent of that coming from the US market. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Contact: Daisy Tsai Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027 Mobile: +886 933-139647 | Line ID : daisy222 Email: daisy@taiwanbio.org.tw BIO Asia-Taiwan 2025 (23-27 July, 2025) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |